Navigation Links
Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
Date:7/23/2008

gational medicines, two of which are in late stages of clinical testing. Duska's ATPace(TM) is expected to enter a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia. Duska's CDP-1050 is expected to commence a Phase 2 clinical trial for the treatment of heart failure. In addition, Duska has a preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For more information, visit http://www.duskatherapeutics.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Duska intends for the forward- looking statements to be covered by the safe harbor provisions for forward- looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Duska are forward-looking statements, including the statements that Duska believes that the proposed single, prospective, placebo-controlled, and randomized trial in patients presenting to the emergency room with paroxysmal supraventricular tachycardia (PSVT) should be sufficient to demonstrate clinical safety and efficacy, that Duska believes that upon successful completion of the proposed Phase 3 trial, it would have all the clinical data necessary to support the filing of the NDA for ATPace(TM) under section 505(b)(2), the belief tha
'/>"/>

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Duska Therapeutics Obtains Standard & Poors Listing
2. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
3. CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008
4. Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
5. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
6. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
7. Organizational Changes at Silence Therapeutics
8. Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases
9. Arno Therapeutics Announces New Ticker Symbol
10. Lorus Therapeutics Receives $600 Thousand From Escrow Account
11. Silence Therapeutics Announces Successful Opposition of Glover Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  Decision Resources Group finds that the majority ... the United States believe that ... be the level of savings achievable by their ... cost to patients. Payers plan to leverage preferential ... expectations in order to encourage physician prescribing of ...
(Date:7/30/2014)... July 30, 2014 A study presented ... safety and efficacy of CSL Behring,s C1 Inhibitor ... transplants in highly sensitized patients. C1-INH is a ... complement system. The study shows that ... in the levels of complement components 3 and ...
(Date:7/30/2014)... Chicago Bears are excited to announce the team,s partnership ... effort to raise awareness of skin cancer. Through this ... skin cancer screenings at a preseason fan event on ... me™ is an educational campaign designed to inform the public, ... cancer, and encourages people to get screened by a ...
(Date:7/30/2014)... LONDON , July 30, 2014  Replikins Ltd. ... structure of the Ebola virus. Before the current outbreaks, ... Replikins per 100 amino acids) between 1995 and 2002 ... 2010, threefold in 2012, and sixteen-fold in 2013, thus ... the past, this technology has been shown to be ...
Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4
... Korea, August 8, 2011Can a flexible LED conformably placed on ... human brain, or rolled upon the blood vessels, diagnose or ... in the near future. The team of Professor Keon ... developed a new concept: a biocompatible, flexible Gallium Nitride (GaN) ...
... (OTCBB: IAGX) announced today that it received an adverse ... its pending dispute with former distributor TriPharma, LLC and ... a private arbitrator and is conducted under the rules ... Diego, California.  The interim award against the Company and ...
... Sept. 19, 2011 Reportlinker.com announces that ... in its catalogue: Established ... http://www.reportlinker.com/p0618133/Established-and-Emerging-Biotech-Clusters.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biotechnology There ... focused clusters of biotechnology companies and related ...
Cached Biology Technology:Established and Emerging Biotech Clusters 2Established and Emerging Biotech Clusters 3Established and Emerging Biotech Clusters 4Established and Emerging Biotech Clusters 5Established and Emerging Biotech Clusters 6Established and Emerging Biotech Clusters 7Established and Emerging Biotech Clusters 8
(Date:7/30/2014)... as simple as inserting a medicated, disappearing fabric minutes ... have discovered a potentially faster way to deliver a ... method spins the drug into silk-like fibers that quickly ... of the drug than possible with other topical materials ... women a potentially more effective, discreet way to protect ...
(Date:7/30/2014)... out how to create colors, nature had already perfected ... many different hues, for example. Now scientists are tapping ... way to make colored plastics. Their paper on using ... rather than dyes, to produce color appears in ... Asger Mortensen, Anders Kristensen and colleagues point out that ...
(Date:7/30/2014)... University Professor Steven Chown has been awarded the ... for Excellence in Antarctic Research. , SCAR, an ... high quality international scientific research in the Antarctic ... region in the Earth system. The organisation also ... Treaty System, responsible for governing the region. , ...
Breaking Biology News(10 mins):Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3
... Mitochondrial diseases disrupt the power generating machinery within cells ... in the lungs or respiratory tract. A new study ... shows that infection with the pneumonia causing bacteria ... a signaling protein that is associated with mitochondrial disease. ...
... Stony Brook, N.Y., July 27, 2009 - Temperature ... amphibians, crustaceans, and lizards live longer at higher latitudes ... week in the Proceedings of the National Academy ... Dr. Stephan Munch and Ph.D. candidate Santiago Salinas, both ...
... Los Angeles, London, New Delhi, Singapore and Washington DC ... special issue of Medical Decision Making , a ... overwhelm hospital resources even with an extremely effective public ... the attack and initiating a response to it. ...
Cached Biology News:Stress signals link pre-existing sickness with susceptibility to bacterial infection 2Warmer environment means shorter lives for cold-blooded animals 2Bioterrorism and disaster preparedness explored in special issue of Medical Decision Making 2
... causing shortages in your laboratory or fellow ... cause unwanted distractions, problems and delays. • ... hard work and endeavour! Bring us your ... and market it internationally. We work under ...
... Perhaps sheer in-house demand is causing shortages ... precious antibody. This can cause unwanted distractions, ... Receive royalties for your hard work ... let us build it up,and market it ...
Topoisomerase I...
...
Biology Products: